肿瘤浸润淋巴细胞和重组人白细胞介素-2对进展期肿瘤患者细胞免疫功能的影响

对20例经手术切除的进展期肿瘤患者用活化的肿瘤浸润淋巴细胞（TIL）和重组人白细胞介素-2（rhIL－2）治疗，检测治疗前后细胞免疫功能变化。其中8例治疗后PBL对同种异体相同组织学类型靶细胞的细胞毒性从43．2升高到1249．0溶解单位（P＜0．05），而NK活性无明显变化；T4、T8淋巴细胞亚群荧光强度明显升高，从1．9到3．9（P＜0．05）及4．4到7．2（P＜0．05）。所有患者PPD及PHA反应性明显增强，从10．9mm到13．6mm（P＜0．01）及7．9mm到12．7mm（P＜0．01），15例有一过性寒战、发热，其中10例伴轻度恶心、呕吐。结果提示：TIL和rhIL－2治疗后可明显提高进展期肿瘤患者的细胞免疫功能，而无明显毒副作用，可能成为进展期肿瘤术后重要的辅助治疗方法。

EFFECT OF AUTOLOGOUS TUMOR INFILTRATING LYMPHOCYTES AND RECOMBINANT HUMAN INTERLEUKIN-2 ON THE CELLULAR IMMUNITY RESPONSE IN PATIENTS WITH ADVANCED TUMOR

Tumor infiltrating lymphocytes(TILs) were isolated from 20 patients with advanced tumor, these cells were cultured in a complete medium supplemented with recombinant interleukin-2 (rIL-2) for 4~6 weeks, cellular immunityresponse was assayed 1 week before and 1 month after TIL infusion. The results showed that cytotoxicity to the same histological type target cells withthe patients was much higher(43. 2 to 1249. 0 Lyticunits, P<0. 05),there was no significant change inNK activity and there was a significant increase offluorescent intensity in T4, T8 subset comparedwith the background in 8 cases (T4: 1. 9 to 3. 9, P<0. 05; T8= 4. 4 to 7. 2, P <0. 05). PPD and PHAskin tests were positive and the skin reactive lesionturned larger in size compared with background in20 cases (PPD: 10. 9 to 13. 6mm, P<0. 01; PHA:7. 9 to 12. 7mm, P<0. 01). 15 patients had transient mild chill and fever, mild nausea and vomitingappeared in 10 of them. All of the above results indicate that TILs plus lower doses of rhIL-2 are ableto improve cellular immunity in patients with advanced tumor without severe-side effect. They mayplay an important role in preventing recurrence andmetastasis.